Physician profile
Taimi Perez
NPI 1992333223
$2,912.93
in general payments reported to CMS, 2019-2025
21 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $243 · 2024: $716 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.65 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $564.44 | 2024-2025 | Zepbound, Mounjaro |
| Madrigal Pharmaceuticals | $445.33 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $186.23 | 2023-2025 | Wainua |
| Lexicon Pharmaceuticals, INC. | $165.55 | 2023-2024 | Inpefa |
| Janssen Biotech, INC. | $146.20 | 2025 | Tremfya |
| Exact Sciences Corporation | $134.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $121.87 | 2025 | |
| Glaxosmithkline, LLC. | $108.49 | 2024-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Pfizer INC. | $55.73 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $47.27 | 2024 | Prolaris |
| Amgen INC. | $38.25 | 2023-2024 | Repatha |
| Bridgebio Pharma, INC. | $29.35 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $28.73 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.23 | 2023 | Onpattro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.07 | 2025 | Freestyle Libre |
| Ardelyx, INC. | $22.28 | 2024 | Ibsrela |
| Dexcom, INC. | $19.36 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.95 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $18.18 | 2024 | |
| Urogen Pharma, INC. | $14.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taimi Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.